| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,830,000 |
| Market
Cap: |
7.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1435 - $0.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
387,903 |
| Total Buy Value |
$0 |
$0 |
$0 |
$173,416 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
2,271,499 |
2,271,499 |
| Total Sell Value |
$0 |
$0 |
$488,749 |
$488,749 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
9 |
9 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brumm Joshua T |
Chief Executive OfficerOfficer |
• • – |
2025-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
268,400 |
|
- |
|
| Mcneill Jonathan |
See RemarksOfficer |
• – – |
2025-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
134,200 |
|
- |
|
| Harwin Peter Evan |
Director |
– • • |
2025-06-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,387,866 |
|
- |
|
| Violin Jonathan |
Director |
– • – |
2025-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
69,515 |
|
- |
|
| Doughty Christopher Grant |
Chief Business OfficerOfficer |
• – – |
2025-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,480 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2025-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,270,004 |
62,383 |
|
- |
|
| Debbane Raymond |
|
– – • |
2024-08-08 |
4 |
S |
$0.19 |
$50,009 |
D/D |
(260,873) |
6,317,565 |
|
-24% |
|
| Debbane Raymond |
|
– – • |
2024-08-07 |
4 |
S |
$0.18 |
$11,197 |
D/D |
(61,488) |
6,578,438 |
|
-38% |
|
| Debbane Raymond |
|
– – • |
2024-08-06 |
4 |
S |
$0.18 |
$10,188 |
D/D |
(55,732) |
6,639,926 |
|
-33% |
|
| Debbane Raymond |
|
– – • |
2024-08-05 |
4 |
S |
$0.19 |
$30,996 |
D/D |
(164,523) |
6,695,658 |
|
-34% |
|
| Debbane Raymond |
|
– – • |
2024-08-02 |
4 |
S |
$0.20 |
$57,354 |
D/D |
(286,200) |
6,860,181 |
|
-38% |
|
| Debbane Raymond |
|
– – • |
2024-08-01 |
4 |
S |
$0.22 |
$13,743 |
D/D |
(63,564) |
7,146,381 |
|
-36% |
|
| Debbane Raymond |
|
– – • |
2024-07-30 |
4 |
S |
$0.22 |
$167,185 |
D/D |
(756,835) |
7,209,945 |
|
-35% |
|
| Debbane Raymond |
|
– – • |
2024-07-29 |
4 |
S |
$0.24 |
$85,637 |
D/D |
(363,949) |
7,966,780 |
|
-22% |
|
| Debbane Raymond |
|
– – • |
2024-07-26 |
4 |
S |
$0.24 |
$62,440 |
D/D |
(258,335) |
8,330,729 |
|
-25% |
|
| Debbane Raymond |
|
– – • |
2024-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,589,064 |
|
32% |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2024-06-21 |
4 |
B |
$0.27 |
$30,717 |
D/D |
115,000 |
680,403 |
0.01 |
77% |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2024-06-20 |
4 |
B |
$0.25 |
$48,108 |
D/D |
190,000 |
565,403 |
0.01 |
96% |
|
| Hahn Brian M. |
SVP Finance, CFO |
• – – |
2024-06-18 |
4 |
B |
$0.25 |
$4,335 |
D/D |
17,500 |
70,643 |
0.01 |
-31% |
|
| Junius Daniel M |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$15,627 |
D/D |
5,209 |
98,459 |
|
- |
|
| Goldberg Mark Alan |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$13,752 |
D/D |
4,584 |
24,828 |
|
- |
|
| King Rachel K. |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$10,002 |
D/D |
3,334 |
515,194 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$13,752 |
D/D |
5,827 |
20,244 |
|
- |
|
| Andrews Patricia S |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$12,251 |
D/D |
5,191 |
58,608 |
|
- |
|
| King Rachel K. |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$10,002 |
D/D |
4,238 |
511,860 |
|
- |
|
124 Records found
|
|
Page 1 of 5 |
|
|
